Drug
Mgcd0103
Mgcd0103: highest development phase Phase 2, developed by Mirati Therapeutics. 7 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Mirati Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| MGCD0103 NCT00359086 | Phase 2 | Lymphoma |
| MGCD0103 NCT00358982 | Phase 2 | Hodgkin's Lymphoma |
| MGCD0103 NCT00431873 | Phase 2 | Lymphocytic Leukemia, Chronic |
| MGCD0103 NCT00372437 | Phase 1/2 | Tumors |
| MGCD0103 NCT00324220 | Phase 1/2 | Myelodysplastic Syndrome |
| MGCD0103 NCT00323934 | Phase 1 | Tumors |
| MGCD0103 NCT00324194 | Phase 1 | Leukemia |
Latest
No recent events.
Follow Mgcd0103 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.